Skip to main content

Table 1 LTT results of patients who had DHR to a combination therapy

From: EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017)

Total pos. LTT

Pos. LTT/%

Pos. LTT/%

Pos. LTT/%

AMX/CLA

Amoxicillin (AMX)

Clavulanic acid (CLA)

Both

n = 115

64 (56%)

12 (10%)

39 (34%)

TMP/SMX

Trimethoprim (TMP)

Sulfamethoxazole (SMX)

Both

n = 37

4 (11%)

16 (43%)

17 (46%)

PIP/TZB

Piperacillin (PIP)

Tazobactam (TZB)

Both

n = 21

7 (33%)

7 (33%)

7 (33%)

Sulfasalazine

Sulfapyridine

5-Aminosalicylic acid (5-ASA)

Both

n = 10

6 (60%)

0 (0%)

4 (40%)

Total n = 183

93 (33–60%)

23 (0–33%)

67 (33–46%)